ID   CBS_HUMAN               Reviewed;         551 AA.
AC   P35520; B2R993; D3DSK4; Q99425; Q9BWC5;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   15-MAR-2017, entry version 199.
DE   RecName: Full=Cystathionine beta-synthase {ECO:0000305};
DE            EC=4.2.1.22 {ECO:0000269|PubMed:20506325, ECO:0000269|PubMed:23974653, ECO:0000269|PubMed:23981774, ECO:0000269|PubMed:25044645};
DE   AltName: Full=Beta-thionase;
DE   AltName: Full=Serine sulfhydrase;
GN   Name=CBS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=7903580; DOI=10.1093/hmg/2.10.1633;
RA   Kraus J.P., Le K., Swaroop M., Ohura T., Tahara T., Rosenberg L.E.,
RA   Roper M.D., Kozich V.;
RT   "Human cystathionine beta-synthase cDNA: sequence, alternative
RT   splicing and expression in cultured cells.";
RL   Hum. Mol. Genet. 2:1633-1638(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=7598711; DOI=10.1006/bbrc.1995.1886;
RA   Chasse J.-F., Paly E., Paris D., Paul V., Sinet P.-M., Kamoun P.,
RA   London J.;
RT   "Genomic organization of the human cystathionine beta-synthase gene:
RT   evidence for various cDNAs.";
RL   Biochem. Biophys. Res. Commun. 211:826-832(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8022826; DOI=10.1073/pnas.91.14.6614;
RA   Kruger W.D., Cox D.R.;
RT   "A yeast system for expression of human cystathionine beta-synthase:
RT   structural and functional conservation of the human and yeast genes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:6614-6618(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9383285; DOI=10.1007/s003359900611;
RA   Chasse J.-F., Paul V., Escanez R., Kamoun P., London J.;
RT   "Human cystathionine beta-synthase: gene organization and expression
RT   of different 5' alternative splicing.";
RL   Mamm. Genome 8:917-921(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING.
RX   PubMed=9790750; DOI=10.1006/geno.1998.5437;
RA   Kraus J.P., Oliveriusova J., Sokolova J., Kraus E., Vlcek C.,
RA   de Franchis R., Maclean K.N., Bao L., Bukovska G., Patterson D.,
RA   Paces V., Ansorge W., Kozich V.;
RT   "The human cystathionine beta-synthase (CBS) gene: complete sequence,
RT   alternative splicing, and polymorphisms.";
RL   Genomics 52:312-324(1998).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10830953; DOI=10.1038/35012518;
RA   Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T.,
RA   Park H.-S., Toyoda A., Ishii K., Totoki Y., Choi D.-K., Groner Y.,
RA   Soeda E., Ohki M., Takagi T., Sakaki Y., Taudien S., Blechschmidt K.,
RA   Polley A., Menzel U., Delabar J., Kumpf K., Lehmann R., Patterson D.,
RA   Reichwald K., Rump A., Schillhabel M., Schudy A., Zimmermann W.,
RA   Rosenthal A., Kudoh J., Shibuya K., Kawasaki K., Asakawa S.,
RA   Shintani A., Sasaki T., Nagamine K., Mitsuyama S., Antonarakis S.E.,
RA   Minoshima S., Shimizu N., Nordsiek G., Hornischer K., Brandt P.,
RA   Scharfe M., Schoen O., Desario A., Reichelt J., Kauer G., Bloecker H.,
RA   Ramser J., Beck A., Klages S., Hennig S., Riesselmann L., Dagand E.,
RA   Wehrmeyer S., Borzym K., Gardiner K., Nizetic D., Francis F.,
RA   Lehrach H., Reinhardt R., Yaspo M.-L.;
RT   "The DNA sequence of human chromosome 21.";
RL   Nature 405:311-319(2000).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   PRO-69.
RC   TISSUE=Brain, Eye, Lung, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   CHARACTERIZATION.
RX   PubMed=681363;
RA   Kraus J.P., Packman S., Fowler B., Rosenberg L.E.;
RT   "Purification and properties of cystathionine beta-synthase from human
RT   liver. Evidence for identical subunits.";
RL   J. Biol. Chem. 253:6523-6528(1978).
RN   [12]
RP   SUMOYLATION AT LYS-211, AND SUBCELLULAR LOCATION.
RX   PubMed=17087506; DOI=10.1021/bi0615644;
RA   Kabil O., Zhou Y., Banerjee R.;
RT   "Human cystathionine beta-synthase is a target for sumoylation.";
RL   Biochemistry 45:13528-13536(2006).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-199, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   CHARACTERIZATION OF VARIANTS CBSD LEU-49; ARG-65; ARG-78; ASN-102;
RP   VAL-114; GLN-125; LYS-144; ARG-148; TYR-165; LYS-176; ALA-180;
RP   MET-191; LYS-228; ARG-262; LYS-266; THR-278; LYS-302; ARG-305;
RP   SER-307; CYS-369; LEU-422; THR-435; GLN-439; ASN-444; LEU-466 AND
RP   SER-539, FUNCTION, CATALYTIC ACTIVITY, PATHWAY, ENZYME REGULATION, AND
RP   SUBUNIT.
RX   PubMed=20506325; DOI=10.1002/humu.21273;
RA   Kozich V., Sokolova J., Klatovska V., Krijt J., Janosik M.,
RA   Jelinek K., Kraus J.P.;
RT   "Cystathionine beta-synthase mutations: effect of mutation topology on
RT   folding and activity.";
RL   Hum. Mutat. 31:809-819(2010).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 1-413 IN COMPLEX WITH
RP   PYRIDOXAL PHOSPHATE AND IRON, SUBUNIT, ENZYME REGULATION, AND REGION.
RX   PubMed=11483494; DOI=10.1093/emboj/20.15.3910;
RA   Meier M., Janosik M., Kery V., Kraus J.P., Burkhard P.;
RT   "Structure of human cystathionine beta-synthase: a unique pyridoxal
RT   5'-phosphate-dependent heme protein.";
RL   EMBO J. 20:3910-3916(2001).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 45-406 IN COMPLEX WITH
RP   PYRIDOXAL PHOSPHATE AND IRON, ALLOSTERIC ACTIVATOR ADOMET, MUTAGENESIS
RP   OF CYS-272 AND CYS-275, AND REGION.
RX   PubMed=12173932; DOI=10.1021/bi026052d;
RA   Taoka S., Lepore B.W., Kabil O., Ojha S., Ringe D., Banerjee R.;
RT   "Human cystathionine beta-synthase is a heme sensor protein. Evidence
RT   that the redox sensor is heme and not the vicinal cysteines in the
RT   CXXC motif seen in the crystal structure of the truncated enzyme.";
RL   Biochemistry 41:10454-10461(2002).
RN   [21]
RP   REVIEW ON CBSD VARIANTS.
RX   PubMed=10338090;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:5<362::AID-HUMU4>3.0.CO;2-K;
RA   Kraus J.P., Janosik M., Kozich V., Mandell R., Shih V.E.,
RA   Sperandeo M.P., Sebastio G., de Franchis R., Andria G.,
RA   Kluijtmans L.A.J., Blom H.J., Boers G.H.J., Gordon R.B., Kamoun P.,
RA   Tsai M.Y., Kruger W.D., Koch H.G., Ohura T., Gaustadnes M.;
RT   "Cystathionine beta-synthase mutations in homocystinuria.";
RL   Hum. Mutat. 13:362-375(1999).
RN   [22]
RP   VARIANT CBSD THR-278.
RX   PubMed=1301198; DOI=10.1002/humu.1380010206;
RA   Kozich V., Kraus J.P.;
RT   "Screening for mutations by expressing patient cDNA segments in E.
RT   coli: homocystinuria due to cystathionine beta-synthase deficiency.";
RL   Hum. Mutat. 1:113-123(1992).
RN   [23]
RP   VARIANTS CBSD VAL-114 AND LEU-145.
RX   PubMed=8353501; DOI=10.1093/hmg/2.6.815;
RA   Kozich V., de Franchis R., Kraus J.P.;
RT   "Molecular defect in a patient with pyridoxine-responsive
RT   homocystinuria.";
RL   Hum. Mol. Genet. 2:815-816(1993).
RN   [24]
RP   VARIANTS CBSD THR-278 AND SER-307.
RX   PubMed=7506602; DOI=10.1093/hmg/2.11.1857;
RA   Hu F.L., Gu Z., Kozich V., Kraus J.P., Ramesh V., Shih V.E.;
RT   "Molecular basis of cystathionine beta-synthase deficiency in
RT   pyridoxine responsive and nonresponsive homocystinuria.";
RL   Hum. Mol. Genet. 2:1857-1860(1993).
RN   [25]
RP   VARIANTS CBSD ARG-78 AND ASN-102.
RX   PubMed=7981678; DOI=10.1093/hmg/3.7.1103;
RA   de Franchis R., Kozich V., McInnes R., Kraus J.P.;
RT   "Identical genotypes in siblings with different homocystinuric
RT   phenotypes: identification of three mutations in cystathionine beta-
RT   synthase using an improved bacterial expression system.";
RL   Hum. Mol. Genet. 3:1103-1108(1994).
RN   [26]
RP   VARIANTS CBSD GLN-125 AND ASP-131.
RX   PubMed=7849717; DOI=10.1093/hmg/3.10.1883;
RA   Marble M., Geraghty M.T., de Franchis R., Kraus J.P., Valle D.;
RT   "Characterization of a cystathionine beta-synthase allele with three
RT   mutations in cis in a patient with B6 nonresponsive homocystinuria.";
RL   Hum. Mol. Genet. 3:1883-1886(1994).
RN   [27]
RP   VARIANTS CBSD.
RX   PubMed=7967489; DOI=10.1007/BF00711354;
RA   Kraus J.P.;
RT   "Komrower Lecture. Molecular basis of phenotype expression in
RT   homocystinuria.";
RL   J. Inherit. Metab. Dis. 17:383-390(1994).
RN   [28]
RP   VARIANTS CBSD ARG-139; LYS-144 AND THR-278.
RX   PubMed=7611293;
RA   Shih V.E., Fringer J.M., Mandell R., Kraus J.P., Berry G.T.,
RA   Heidenreich R.A., Korson M.S., Levy H.L., Ramesh V.;
RT   "A missense mutation (I278T) in the cystathionine beta-synthase gene
RT   prevalent in pyridoxine-responsive homocystinuria and associated with
RT   mild clinical phenotype.";
RL   Am. J. Hum. Genet. 57:34-39(1995).
RN   [29]
RP   VARIANTS CBSD SER-88; GLN-125 AND MET-257.
RX   PubMed=7762555;
RA   Sebastio G., Sperandeo M.P., Panico M., de Franchis R., Kraus J.P.,
RA   Andria G.;
RT   "The molecular basis of homocystinuria due to cystathionine beta-
RT   synthase deficiency in Italian families, and report of four novel
RT   mutations.";
RL   Am. J. Hum. Genet. 56:1324-1333(1995).
RN   [30]
RP   VARIANTS CBSD TYR-165 AND MET-371.
RX   PubMed=7635485; DOI=10.1007/BF00207394;
RA   Kluijtmans L.A.J., Blom H.J., Boers G.H.J., van Oost B.A.,
RA   Trijbels F.J.M., van den Heuvel L.P.W.J.;
RT   "Two novel missense mutations in the cystathionine beta-synthase gene
RT   in homocystinuric patients.";
RL   Hum. Genet. 96:249-250(1995).
RN   [31]
RP   VARIANTS CBSD MET-168; HIS-224; THR-278; SER-307; VAL-331 AND GLU-454.
RX   PubMed=8528202; DOI=10.1093/hmg/4.7.1155;
RA   Kruger W.D., Cox D.R.;
RT   "A yeast assay for functional detection of mutations in the human
RT   cystathionine beta-synthase gene.";
RL   Hum. Mol. Genet. 4:1155-1161(1995).
RN   [32]
RP   VARIANT CBSD LEU-290.
RX   PubMed=7564249; DOI=10.1007/BF00711769;
RA   Sperandeo M.P., Panico M., Pepe A., Candito M., de Franchis R.,
RA   Kraus J.P., Andria G., Sebastio G.;
RT   "Molecular analysis of patients affected by homocystinuria due to
RT   cystathionine beta-synthase deficiency: report of a new mutation in
RT   exon 8 and a deletion in intron 11.";
RL   J. Inherit. Metab. Dis. 18:211-214(1995).
RN   [33]
RP   VARIANT CBSD ASN-444, AND CHARACTERIZATION OF VARIANT CBSD ASN-444.
RX   PubMed=8755636; DOI=10.1172/JCI118791;
RA   Kluijtmans L.A.J., Boers G.H.J., Stevens E.M.B., Renier W.O.,
RA   Kraus J.P., Trijbels F.J.M., van den Heuvel L.P.W.J., Blom H.J.;
RT   "Defective cystathionine beta-synthase regulation by S-
RT   adenosylmethionine in a partially pyridoxine responsive homocystinuria
RT   patient.";
RL   J. Clin. Invest. 98:285-289(1996).
RN   [34]
RP   VARIANTS CBSD ARG-116; THR-278 AND LEU-290.
RX   PubMed=8803779; DOI=10.1007/BF01799266;
RA   Sperandeo M.P., Candito M., Sebastio G., Rolland M.O., Turc-Carel C.,
RA   Giudicelli H., Dellamonica P., Andria G.;
RT   "Homocysteine response to methionine challenge in four obligate
RT   heterozygotes for homocystinuria and relationship with cystathionine
RT   beta-synthase mutations.";
RL   J. Inherit. Metab. Dis. 19:351-356(1996).
RN   [35]
RP   VARIANTS CBSD LYS-144; THR-278; GLU-331; MET-353 AND GLN-439.
RX   PubMed=9156316;
RA   Dawson P.A., Cox A.J., Emmerson B.T., Dudman N.P.B., Kraus J.P.,
RA   Gordon R.B.;
RT   "Characterisation of five missense mutations in the cystathionine
RT   beta-synthase gene from three patients with B6-nonresponsive
RT   homocystinuria.";
RL   Eur. J. Hum. Genet. 5:15-21(1997).
RN   [36]
RP   VARIANTS CBSD MET-262; LYS-266; THR-278; SER-307; ALA-320 AND CYS-369.
RX   PubMed=9361025; DOI=10.1093/hmg/6.13.2213;
RA   Kim C.E., Gallagher P.M., Guttormsen A.B., Refsum H., Ueland P.M.,
RA   Ose L., Foelling I., Whitehead A.S., Tsai M.Y., Kruger W.D.;
RT   "Functional modeling of vitamin responsiveness in yeast: a common
RT   pyridoxine-responsive cystathionine beta-synthase mutation in
RT   homocystinuria.";
RL   Hum. Mol. Genet. 6:2213-2221(1997).
RN   [37]
RP   VARIANTS CBSD GLU-384 AND SER-539.
RX   PubMed=8990018;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:1<81::AID-HUMU18>3.3.CO;2-S;
RA   Aral B., Coude M., London J., Aupetit J., Chasse J.-F., Zabot M.-T.,
RA   Chadefaux-Vekemans B., Kamoun P.;
RT   "Two novel mutations (K384E and L539S) in the C-terminal moiety of the
RT   cystathionine beta-synthase protein in two French pyridoxine-
RT   responsive homocystinuria patients.";
RL   Hum. Mutat. 9:81-82(1997).
RN   [38]
RP   VARIANTS CBSD LYS-176; THR-278 AND SER-307.
RX   PubMed=9266356; DOI=10.1023/A:1005325911665;
RA   Kozich V., Janosik M., Sokolova J., Oliveriusova J., Orendac M.,
RA   Kraus J.P., Elleder D.;
RT   "Analysis of CBS alleles in Czech and Slovak patients with
RT   homocystinuria: report on three novel mutations E176K, W409X and 1223
RT   + 37 del99.";
RL   J. Inherit. Metab. Dis. 20:363-366(1997).
RN   [39]
RP   VARIANTS CBSD TYR-370 AND GLN-439.
RX   PubMed=10462600; DOI=10.1054/MODI00200129;
RA   Tsai M.Y., Wong P.W.K., Garg U., Hanson N.Q., Schwichtenberg K.;
RT   "Two novel mutations in the cystathionine beta-synthase gene of
RT   homocystinuric patients.";
RL   Mol. Diagn. 2:129-133(1997).
RN   [40]
RP   VARIANTS CBSD LYS-144 AND TYR-165.
RX   PubMed=10215408;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:4<332::AID-HUMU15>3.0.CO;2-S;
RA   Gordon R.B., Cox A.J., Dawson P.A., Emmerson B.T., Kraus J.P.,
RA   Dudman N.P.;
RT   "Mutational analysis of the cystathionine beta-synthase gene: a
RT   splicing mutation, two missense mutations and an insertion in patients
RT   with homocystinuria.";
RL   Hum. Mutat. 11:332-332(1998).
RN   [41]
RP   VARIANTS CBSD PRO-101; LYS-228; MET-262; THR-278; SER-307 AND PRO-355.
RX   PubMed=9889017; DOI=10.1006/mgme.1998.2771;
RA   Gallagher P.M., Naughten E., Hanson N.Q., Schwichtenberg K.,
RA   Bignell M., Yuan M., Ward P., Yap S., Whitehead A.S., Tsai M.Y.;
RT   "Characterization of mutations in the cystathionine beta-synthase gene
RT   in Irish patients with homocystinuria.";
RL   Mol. Genet. Metab. 65:298-302(1998).
RN   [42]
RP   VARIANTS CBSD TRP-58; VAL-126; LYS-302 AND CYS-336.
RX   PubMed=10408774;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:6<453::AID-HUMU4>3.0.CO;2-K;
RA   de Franchis R., Kraus E., Kozich V., Sebastio G., Kraus J.P.;
RT   "Four novel mutations in the cystathionine beta-synthase gene: effect
RT   of a second linked mutation on the severity of the homocystinuric
RT   phenotype.";
RL   Hum. Mutat. 13:453-457(1999).
RN   [43]
RP   VARIANTS CBSD GLN-102; ARG-262 AND THR-278.
RX   PubMed=11013450;
RX   DOI=10.1002/1098-1004(200010)16:4<372::AID-HUMU12>3.0.CO;2-J;
RA   Gat-Yablonski G., Mandel H., Fowler B., Taleb O., Sela B.-A.;
RT   "Homocystinuria in the Arab population of Israel: identification of
RT   two novel mutations using DGGE analysis.";
RL   Hum. Mutat. 16:372-372(2000).
RN   [44]
RP   VARIANTS CBSD ARG-65; VAL-114; LYS-144; THR-155; TYR-165; LYS-176 AND
RP   THR-278, AND CHARACTERIZATION OF VARIANTS CBSD VAL-114; LYS-144;
RP   THR-155; TYR-165; LYS-176 AND THR-278.
RX   PubMed=11359213; DOI=10.1086/320597;
RA   Janosik M., Oliveriusova J., Janosikova B., Sokolova J., Kraus E.,
RA   Kraus J.P., Kozich V.;
RT   "Impaired heme binding and aggregation of mutant cystathionine beta-
RT   synthase subunits in homocystinuria.";
RL   Am. J. Hum. Genet. 68:1506-1513(2001).
RN   [45]
RP   VARIANTS CBSD PRO-125 AND THR-361.
RX   PubMed=11553052; DOI=10.1034/j.1399-0004.2001.600212.x;
RA   Castro R., Heil S.G., Rivera I., Jakobs C., de Almeida I.T.,
RA   Blom H.J.;
RT   "Molecular genetic analysis of the cystathionine beta-synthase gene in
RT   Portuguese homocystinuria patients: three novel mutations.";
RL   Clin. Genet. 60:161-163(2001).
RN   [46]
RP   VARIANTS CBSD ARG-85; THR-278; LEU-422; THR-435; ASN-444 AND LEU-466,
RP   AND CHARACTERIZATION OF VARIANTS CBSD ARG-85; LEU-422; THR-435 AND
RP   LEU-466.
RX   PubMed=12007221; DOI=10.1002/humu.10089;
RA   Maclean K.N., Gaustadnes M., Oliveriusova J., Janosik M., Kraus E.,
RA   Kozich V., Kery V., Skovby F., Ruediger N., Ingerslev J.,
RA   Stabler S.P., Allen R.H., Kraus J.P.;
RT   "High homocysteine and thrombosis without connective tissue disorders
RT   are associated with a novel class of cystathionine beta-synthase (CBS)
RT   mutations.";
RL   Hum. Mutat. 19:641-655(2002).
RN   [47]
RP   VARIANTS CBSD LEU-49; PRO-101; ARG-109; GLN-125; LYS-144; TYR-165;
RP   LYS-228; THR-278; LYS-302; SER-307; GLU-331; CYS-336; SER-347;
RP   MET-353; CYS-369; MET-371 AND GLN-439, AND CHARACTERIZATION OF
RP   VARIANTS CBSD PRO-101; ARG-109; LYS-228 AND SER-347.
RX   PubMed=12124992; DOI=10.1002/humu.10104;
RA   Gaustadnes M., Wilcken B., Oliveriusova J., McGill J., Fletcher J.,
RA   Kraus J.P., Wilcken D.E.;
RT   "The molecular basis of cystathionine beta-synthase deficiency in
RT   Australian patients: genotype-phenotype correlations and response to
RT   treatment.";
RL   Hum. Mutat. 20:117-126(2002).
RN   [48]
RP   VARIANTS CBSD TRP-125; MET-191; TYR-275; CYS-336; PRO-338; ASN-349;
RP   GLN-379 AND PRO-456.
RX   PubMed=12815602; DOI=10.1002/humu.9153;
RA   Urreizti R., Balcells S., Rodes M., Vilarinho L., Baldellou A.,
RA   Couce M.L., Munoz C., Campistol J., Pinto X., Vilaseca M.A.,
RA   Grinberg D.;
RT   "Spectrum of CBS mutations in 16 homocystinuric patients from the
RT   iberian peninsula: high prevalence of T191M and absence of I278T or
RT   G307S.";
RL   Hum. Mutat. 22:103-103(2003).
RN   [49]
RP   VARIANTS CBSD PRO-101; THR-226; SER-228; PRO-231; THR-278; SER-307;
RP   ALA-320; MET-353; ASN-376 AND LYS-526, AND CHARACTERIZATION OF
RP   VARIANTS CBSD PRO-101; THR-226; SER-228; PRO-231; THR-278; SER-307;
RP   ALA-320; MET-353; ASN-376 AND LYS-526.
RX   PubMed=14635102; DOI=10.1002/humu.10290;
RA   Kruger W.D., Wang L., Jhee K.H., Singh R.H., Elsas L.J. II;
RT   "Cystathionine beta-synthase deficiency in Georgia (USA): correlation
RT   of clinical and biochemical phenotype with genotype.";
RL   Hum. Mutat. 22:434-441(2003).
RN   [50]
RP   VARIANTS CBSD MET-143; ARG-148; LYS-228 AND THR-278, AND
RP   CHARACTERIZATION OF VARIANTS CBSD MET-143 AND ARG-148.
RX   PubMed=15146473; DOI=10.1002/humu.9249;
RA   Orendac M., Pronicka E., Kubalska J., Janosik M., Sokolova J.,
RA   Linnebank M., Koch H.G., Kozich V.;
RT   "Identification and functional analysis of two novel mutations in the
RT   CBS gene in Polish patients with homocystinuria.";
RL   Hum. Mutat. 23:631-631(2004).
RN   [51]
RP   VARIANTS CBSD 247-LYS--GLY-256 DEL; PRO-288 AND TRP-379.
RX   PubMed=15365998; DOI=10.1002/humu.9280;
RA   Linnebank M., Janosik M., Kozich V., Pronicka E., Kubalska J.,
RA   Sokolova J., Linnebank A., Schmidt E., Leyendecker C., Klockgether T.,
RA   Kraus J.P., Koch H.G.;
RT   "The cystathionine beta-synthase (CBS) mutation c.1224-2A>C in Central
RT   Europe: vitamin B6 nonresponsiveness and a common ancestral
RT   haplotype.";
RL   Hum. Mutat. 24:352-353(2004).
RN   [52]
RP   VARIANTS CBSD ALA-168; MET-191 AND THR-278.
RX   PubMed=15993874; DOI=10.1016/j.cccn.2005.05.030;
RA   Porto M.P.R., Galdieri L.C., Pereira V.G., Vergani N.,
RA   da Rocha J.C.C., Micheletti C., Martins A.M., Perez A.B.A.,
RA   Almeida V.D.;
RT   "Molecular analysis of homocystinuria in Brazilian patients.";
RL   Clin. Chim. Acta 362:71-78(2005).
RN   [53]
RP   VARIANTS CBSD GLN-154; VAL-155; ASP-234 DEL; MET-257; THR-288;
RP   CYS-336; SER-347 AND MET-353, VARIANT CYS-18, CHARACTERIZATION OF
RP   VARIANTS CBSD GLN-154; VAL-155; ASP-234 DEL; MET-257; THR-288;
RP   CYS-336; SER-347 AND MET-353, AND CHARACTERIZATION OF VARIANT CYS-18.
RX   PubMed=16205833; DOI=10.1007/s10038-005-0312-2;
RA   Lee S.-J., Lee D.H., Yoo H.-W., Koo S.K., Park E.-S., Park J.-W.,
RA   Lim H.G., Jung S.-C.;
RT   "Identification and functional analysis of cystathionine beta-synthase
RT   gene mutations in patients with homocystinuria.";
RL   J. Hum. Genet. 50:648-654(2005).
RN   [54]
RP   CHARACTERIZATION OF VARIANTS CBSD TRP-125; ARG-148; VAL-173; MET-191;
RP   THR-226; TYR-275; CYS-336; HIS-336; PRO-338; ASN-349; GLN-379 AND
RP   PRO-456, AND CHARACTERIZATION OF VARIANT GLN-548.
RX   PubMed=16429402; DOI=10.1002/humu.9395;
RA   Urreizti R., Asteggiano C., Cozar M., Frank N., Vilaseca M.A.,
RA   Grinberg D., Balcells S.;
RT   "Functional assays testing pathogenicity of 14 cystathionine-beta
RT   synthase mutations.";
RL   Hum. Mutat. 27:211-211(2006).
RN   [55]
RP   VARIANTS CBSD MET-173 DEL; LEU-200; SER-278; ASN-281; VAL-321 AND
RP   SER-446, AND CHARACTERIZATION OF VARIANTS CBSD MET-173 DEL; SER-278;
RP   ASN-281 AND VAL-321.
RX   PubMed=21520339; DOI=10.1002/humu.21514;
RA   Cozar M., Urreizti R., Vilarinho L., Grosso C., Dodelson de Kremer R.,
RA   Asteggiano C.G., Dalmau J., Garcia A.M., Vilaseca M.A., Grinberg D.,
RA   Balcells S.;
RT   "Identification and functional analyses of CBS alleles in Spanish and
RT   Argentinian homocystinuric patients.";
RL   Hum. Mutat. 32:835-842(2011).
RN   [56]
RP   VARIANTS CBSD THR-278 AND CYS-336.
RX   PubMed=21240075; DOI=10.1097/PAT.0b013e3283419dbb;
RA   Kwok J.S., Fung S.L., Lui G.C., Law E.L., Chan M.H., Leung C.B.,
RA   Tang N.L.;
RT   "CBS gene mutations found in a Chinese pyridoxine-responsive
RT   homocystinuria patient.";
RL   Pathology 43:81-83(2011).
RN   [57]
RP   VARIANT CBSD LYS-266, CHARACTERIZATION OF VARIANT CBSD LYS-266, AND
RP   ENZYME REGULATION.
RX   PubMed=22738154; DOI=10.1021/bi300421z;
RA   Smith A.T., Su Y., Stevens D.J., Majtan T., Kraus J.P., Burstyn J.N.;
RT   "Effect of the disease-causing R266K mutation on the heme and PLP
RT   environments of human cystathionine beta-synthase.";
RL   Biochemistry 51:6360-6370(2012).
RN   [58]
RP   VARIANTS CBSD ARG-85; ASN-87 AND ASN-234, CHARACTERIZATION OF VARIANTS
RP   CBSD ASN-87 AND ASN-234, FUNCTION, CATALYTIC ACTIVITY, PATHWAY,
RP   COFACTOR, SUBCELLULAR LOCATION, AND SUBUNIT.
RX   PubMed=23981774; DOI=10.1016/j.gene.2013.08.021;
RA   Casique L., Kabil O., Banerjee R., Martinez J.C., De Lucca M.;
RT   "Characterization of two pathogenic mutations in cystathionine beta-
RT   synthase: different intracellular locations for wild-type and mutant
RT   proteins.";
RL   Gene 531:117-124(2013).
RN   [59]
RP   VARIANT CBSD GLY-449, CHARACTERIZATION OF VARIANTS CBSD LEU-427;
RP   ASN-444; GLY-449; LEU-500 AND GLN-540, AND CATALYTIC ACTIVITY.
RX   PubMed=25044645; DOI=10.1002/humu.22616;
RA   Mendes M.I., Santos A.S., Smith D.E., Lino P.R., Colaco H.G.,
RA   de Almeida I.T., Vicente J.B., Salomons G.S., Rivera I., Blom H.J.,
RA   Leandro P.;
RT   "Insights into the regulatory domain of cystathionine Beta-synthase:
RT   characterization of six variant proteins.";
RL   Hum. Mutat. 35:1195-1202(2014).
RN   [60]
RP   VARIANTS CBSD LEU-49; LYS-269 DEL; THR-278; HIS-336; LEU-427; ASN-444;
RP   LEU-500 AND GLN-540, CHARACTERIZATION OF VARIANTS CBSD LEU-49; LYS-269
RP   DEL; THR-278; HIS-336; LEU-427; ASN-444; LEU-500 AND GLN-540,
RP   FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND ENZYME REGULATION.
RX   PubMed=23974653; DOI=10.1007/s10545-013-9647-6;
RA   Mendes M.I., Colaco H.G., Smith D.E., Ramos R.J., Pop A.,
RA   van Dooren S.J., Tavares de Almeida I., Kluijtmans L.A., Janssen M.C.,
RA   Rivera I., Salomons G.S., Leandro P., Blom H.J.;
RT   "Reduced response of Cystathionine Beta-Synthase (CBS) to S-
RT   Adenosylmethionine (SAM): Identification and functional analysis of
RT   CBS gene mutations in Homocystinuria patients.";
RL   J. Inherit. Metab. Dis. 37:245-254(2014).
CC   -!- FUNCTION: Hydro-lyase catalyzing the first step of the
CC       transsulfuration pathway, where the hydroxyl group of L-serine is
CC       displaced by L-homocysteine in a beta-replacement reaction to form
CC       L-cystathionine, the precursor of L-cysteine. This catabolic route
CC       allows the elimination of L-methionine and the toxic metabolite L-
CC       homocysteine (PubMed:23981774, PubMed:20506325, PubMed:23974653).
CC       Also involved in the production of hydrogen sulfide, a
CC       gasotransmitter with signaling and cytoprotective effects on
CC       neurons (By similarity). {ECO:0000250|UniProtKB:P32232,
CC       ECO:0000269|PubMed:20506325, ECO:0000269|PubMed:23974653,
CC       ECO:0000269|PubMed:23981774}.
CC   -!- CATALYTIC ACTIVITY: L-serine + L-homocysteine = L-cystathionine +
CC       H(2)O. {ECO:0000269|PubMed:20506325, ECO:0000269|PubMed:23974653,
CC       ECO:0000269|PubMed:23981774, ECO:0000269|PubMed:25044645}.
CC   -!- COFACTOR:
CC       Name=pyridoxal 5'-phosphate; Xref=ChEBI:CHEBI:597326;
CC         Evidence={ECO:0000269|PubMed:23981774};
CC   -!- ENZYME REGULATION: Allosterically activated by S-adenosyl-
CC       methionine/AdoMet. Activated by S-adenosylhomocysteine/AdoHcy
CC       (PubMed:20506325). Binds non-covalently to a heme group that may
CC       control the redox sensitivity of the enzyme (PubMed:11483494,
CC       PubMed:12173932, PubMed:22738154). {ECO:0000269|PubMed:11483494,
CC       ECO:0000269|PubMed:12173932, ECO:0000269|PubMed:20506325,
CC       ECO:0000269|PubMed:22738154, ECO:0000269|PubMed:23974653}.
CC   -!- PATHWAY: Amino-acid biosynthesis; L-cysteine biosynthesis; L-
CC       cysteine from L-homocysteine and L-serine: step 1/2.
CC       {ECO:0000269|PubMed:20506325, ECO:0000269|PubMed:23974653,
CC       ECO:0000269|PubMed:23981774}.
CC   -!- SUBUNIT: Homotetramer. {ECO:0000269|PubMed:11483494,
CC       ECO:0000269|PubMed:12173932, ECO:0000269|PubMed:20506325,
CC       ECO:0000269|PubMed:23981774}.
CC   -!- INTERACTION:
CC       Self; NbExp=4; IntAct=EBI-740135, EBI-740135;
CC       Q08426:EHHADH; NbExp=3; IntAct=EBI-740135, EBI-2339219;
CC       Q13526:PIN1; NbExp=3; IntAct=EBI-740135, EBI-714158;
CC       P54619:PRKAG1; NbExp=3; IntAct=EBI-740135, EBI-1181439;
CC       P25786:PSMA1; NbExp=3; IntAct=EBI-740135, EBI-359352;
CC       P57075:UBASH3A; NbExp=3; IntAct=EBI-740135, EBI-2105393;
CC       Q7KZS0:UBE2I; NbExp=3; IntAct=EBI-740135, EBI-10180829;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17087506,
CC       ECO:0000269|PubMed:23981774}. Nucleus
CC       {ECO:0000269|PubMed:17087506}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Major;
CC         IsoId=P35520-1; Sequence=Displayed;
CC       Name=2; Synonyms=Minor;
CC         IsoId=P35520-2; Sequence=VSP_001217;
CC   -!- TISSUE SPECIFICITY: In the adult strongly expressed in liver and
CC       pancreas, some expression in heart and brain, weak expression in
CC       lung and kidney. In the fetus, expressed in brain, liver and
CC       kidney.
CC   -!- DISEASE: Cystathionine beta-synthase deficiency (CBSD)
CC       [MIM:236200]: An enzymatic deficiency resulting in altered sulfur
CC       metabolism and homocystinuria. The clinical features of untreated
CC       homocystinuria due to CBS deficiency include myopia, ectopia
CC       lentis, mental retardation, skeletal anomalies resembling Marfan
CC       syndrome, and thromboembolic events. Light skin and hair can also
CC       be present. Biochemical features include increased urinary
CC       homocystine and methionine. {ECO:0000269|PubMed:10215408,
CC       ECO:0000269|PubMed:10408774, ECO:0000269|PubMed:10462600,
CC       ECO:0000269|PubMed:11013450, ECO:0000269|PubMed:11359213,
CC       ECO:0000269|PubMed:11553052, ECO:0000269|PubMed:12007221,
CC       ECO:0000269|PubMed:12124992, ECO:0000269|PubMed:12815602,
CC       ECO:0000269|PubMed:1301198, ECO:0000269|PubMed:14635102,
CC       ECO:0000269|PubMed:15146473, ECO:0000269|PubMed:15365998,
CC       ECO:0000269|PubMed:15993874, ECO:0000269|PubMed:16205833,
CC       ECO:0000269|PubMed:16429402, ECO:0000269|PubMed:20506325,
CC       ECO:0000269|PubMed:21240075, ECO:0000269|PubMed:21520339,
CC       ECO:0000269|PubMed:22738154, ECO:0000269|PubMed:23974653,
CC       ECO:0000269|PubMed:23981774, ECO:0000269|PubMed:25044645,
CC       ECO:0000269|PubMed:7506602, ECO:0000269|PubMed:7564249,
CC       ECO:0000269|PubMed:7611293, ECO:0000269|PubMed:7635485,
CC       ECO:0000269|PubMed:7762555, ECO:0000269|PubMed:7849717,
CC       ECO:0000269|PubMed:7967489, ECO:0000269|PubMed:7981678,
CC       ECO:0000269|PubMed:8353501, ECO:0000269|PubMed:8528202,
CC       ECO:0000269|PubMed:8755636, ECO:0000269|PubMed:8803779,
CC       ECO:0000269|PubMed:8990018, ECO:0000269|PubMed:9156316,
CC       ECO:0000269|PubMed:9266356, ECO:0000269|PubMed:9361025,
CC       ECO:0000269|PubMed:9889017}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the cysteine synthase/cystathionine beta-
CC       synthase family. {ECO:0000305}.
CC   -!- CAUTION: There is a duplication of the CBS gene on chromosome 21.
CC       CBS, which was originally identified as the gene encoding
CC       cystathionine beta-synthase, and CBSL (AC P12345) encode identical
CC       proteins. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=CBS mutation database;
CC       URL="http://cbs.lf1.cuni.cz/index.php";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L19501; AAA19874.1; -; mRNA.
DR   EMBL; X82166; CAA57656.1; -; mRNA.
DR   EMBL; L14577; AAA98524.1; -; mRNA.
DR   EMBL; X88562; CAA61252.1; -; Genomic_DNA.
DR   EMBL; X91910; CAA61252.1; JOINED; Genomic_DNA.
DR   EMBL; X98811; CAA61252.1; JOINED; Genomic_DNA.
DR   EMBL; X98812; CAA61252.1; JOINED; Genomic_DNA.
DR   EMBL; X98813; CAA61252.1; JOINED; Genomic_DNA.
DR   EMBL; X98814; CAA61252.1; JOINED; Genomic_DNA.
DR   EMBL; X98815; CAA61252.1; JOINED; Genomic_DNA.
DR   EMBL; X98816; CAA61252.1; JOINED; Genomic_DNA.
DR   EMBL; X98817; CAA61252.1; JOINED; Genomic_DNA.
DR   EMBL; X98818; CAA61252.1; JOINED; Genomic_DNA.
DR   EMBL; X98819; CAA61252.1; JOINED; Genomic_DNA.
DR   EMBL; X98820; CAA61252.1; JOINED; Genomic_DNA.
DR   EMBL; X98821; CAA61252.1; JOINED; Genomic_DNA.
DR   EMBL; X98822; CAA61252.1; JOINED; Genomic_DNA.
DR   EMBL; X98823; CAA61252.1; JOINED; Genomic_DNA.
DR   EMBL; AF042836; AAC64684.1; -; Genomic_DNA.
DR   EMBL; AF042836; AAC64683.1; -; Genomic_DNA.
DR   EMBL; BT007154; AAP35818.1; -; mRNA.
DR   EMBL; AK313691; BAG36440.1; -; mRNA.
DR   EMBL; AP001630; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471079; EAX09508.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09509.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09510.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09511.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09515.1; -; Genomic_DNA.
DR   EMBL; BC000440; AAH00440.1; -; mRNA.
DR   EMBL; BC007257; AAH07257.1; -; mRNA.
DR   EMBL; BC010242; AAH10242.1; -; mRNA.
DR   EMBL; BC011381; AAH11381.1; -; mRNA.
DR   CCDS; CCDS13693.1; -. [P35520-1]
DR   PIR; A55760; A55760.
DR   RefSeq; NP_000062.1; NM_000071.2. [P35520-1]
DR   RefSeq; NP_001171479.1; NM_001178008.2. [P35520-1]
DR   RefSeq; NP_001171480.1; NM_001178009.2. [P35520-1]
DR   RefSeq; NP_001307227.1; NM_001320298.1. [P35520-1]
DR   RefSeq; NP_001308002.1; NM_001321073.1. [P35520-1]
DR   RefSeq; XP_011528079.1; XM_011529777.1. [P35520-2]
DR   RefSeq; XP_011528083.1; XM_011529781.1. [P35520-2]
DR   RefSeq; XP_011528084.1; XM_011529782.1. [P35520-2]
DR   RefSeq; XP_011544396.1; XM_011546094.1. [P35520-2]
DR   RefSeq; XP_011544397.1; XM_011546095.2. [P35520-2]
DR   RefSeq; XP_011544399.1; XM_011546097.2. [P35520-2]
DR   RefSeq; XP_011544400.1; XM_011546098.1. [P35520-2]
DR   RefSeq; XP_011544401.1; XM_011546099.1. [P35520-1]
DR   RefSeq; XP_016883700.1; XM_017028211.1. [P35520-2]
DR   RefSeq; XP_016883701.1; XM_017028212.1. [P35520-2]
DR   RefSeq; XP_016883702.1; XM_017028213.1. [P35520-2]
DR   RefSeq; XP_016883703.1; XM_017028214.1. [P35520-1]
DR   RefSeq; XP_016883704.1; XM_017028215.1. [P35520-1]
DR   RefSeq; XP_016883705.1; XM_017028216.1. [P35520-1]
DR   RefSeq; XP_016883706.1; XM_017028217.1. [P35520-1]
DR   RefSeq; XP_016883707.1; XM_017028218.1. [P35520-1]
DR   RefSeq; XP_016883978.1; XM_017028489.1. [P35520-2]
DR   RefSeq; XP_016883979.1; XM_017028490.1. [P35520-1]
DR   RefSeq; XP_016883980.1; XM_017028491.1. [P35520-1]
DR   RefSeq; XP_016883981.1; XM_017028492.1. [P35520-1]
DR   UniGene; Hs.533013; -.
DR   PDB; 1JBQ; X-ray; 2.60 A; A/B/C/D/E/F=2-413.
DR   PDB; 1M54; X-ray; 2.90 A; A/B/C/D/E/F=44-406.
DR   PDB; 4COO; X-ray; 2.00 A; A/B=1-551.
DR   PDB; 4L0D; X-ray; 2.97 A; A/B=1-551.
DR   PDB; 4L27; X-ray; 3.39 A; A/B/C/D=2-551.
DR   PDB; 4L28; X-ray; 2.63 A; A/B/C/D=2-551.
DR   PDB; 4L3V; X-ray; 3.63 A; A/B/C=2-551.
DR   PDB; 4PCU; X-ray; 3.58 A; A/B=1-551.
DR   PDB; 4UUU; X-ray; 1.71 A; A/B=406-547.
DR   PDBsum; 1JBQ; -.
DR   PDBsum; 1M54; -.
DR   PDBsum; 4COO; -.
DR   PDBsum; 4L0D; -.
DR   PDBsum; 4L27; -.
DR   PDBsum; 4L28; -.
DR   PDBsum; 4L3V; -.
DR   PDBsum; 4PCU; -.
DR   PDBsum; 4UUU; -.
DR   ProteinModelPortal; P35520; -.
DR   SMR; P35520; -.
DR   BioGrid; 107321; 66.
DR   IntAct; P35520; 23.
DR   MINT; MINT-133409; -.
DR   STRING; 9606.ENSP00000344460; -.
DR   BindingDB; P35520; -.
DR   ChEMBL; CHEMBL3399911; -.
DR   DrugBank; DB00151; L-Cysteine.
DR   DrugBank; DB00133; L-Serine.
DR   DrugBank; DB00114; Pyridoxal Phosphate.
DR   DrugBank; DB00118; S-Adenosylmethionine.
DR   GuidetoPHARMACOLOGY; 1443; -.
DR   iPTMnet; P35520; -.
DR   PhosphoSitePlus; P35520; -.
DR   BioMuta; CBS; -.
DR   DMDM; 543959; -.
DR   EPD; P35520; -.
DR   MaxQB; P35520; -.
DR   PaxDb; P35520; -.
DR   PeptideAtlas; P35520; -.
DR   PRIDE; P35520; -.
DR   DNASU; 875; -.
DR   Ensembl; ENST00000352178; ENSP00000344460; ENSG00000160200. [P35520-1]
DR   Ensembl; ENST00000359624; ENSP00000352643; ENSG00000160200. [P35520-1]
DR   Ensembl; ENST00000398158; ENSP00000381225; ENSG00000160200. [P35520-1]
DR   Ensembl; ENST00000398165; ENSP00000381231; ENSG00000160200. [P35520-1]
DR   GeneID; 102724560; -.
DR   GeneID; 875; -.
DR   KEGG; hsa:102724560; -.
DR   KEGG; hsa:875; -.
DR   UCSC; uc002zct.3; human. [P35520-1]
DR   CTD; 102724560; -.
DR   CTD; 875; -.
DR   DisGeNET; 102724560; -.
DR   DisGeNET; 875; -.
DR   GeneCards; CBS; -.
DR   GeneReviews; CBS; -.
DR   HGNC; HGNC:1550; CBS.
DR   HPA; HPA001223; -.
DR   MalaCards; CBS; -.
DR   MIM; 236200; phenotype.
DR   MIM; 613381; gene.
DR   neXtProt; NX_P35520; -.
DR   OpenTargets; ENSG00000160200; -.
DR   OpenTargets; ENSG00000274276; -.
DR   Orphanet; 394; Classical homocystinuria.
DR   PharmGKB; PA26123; -.
DR   eggNOG; KOG1252; Eukaryota.
DR   eggNOG; COG0031; LUCA.
DR   GeneTree; ENSGT00510000047027; -.
DR   HOGENOM; HOG000217392; -.
DR   HOVERGEN; HBG000918; -.
DR   InParanoid; P35520; -.
DR   KO; K01697; -.
DR   OMA; WMASYGF; -.
DR   OrthoDB; EOG091G02TP; -.
DR   PhylomeDB; P35520; -.
DR   TreeFam; TF300784; -.
DR   BioCyc; MetaCyc:HS08461-MONOMER; -.
DR   BRENDA; 4.2.1.22; 2681.
DR   Reactome; R-HSA-1614603; Cysteine formation from homocysteine.
DR   Reactome; R-HSA-2408508; Metabolism of ingested SeMet, Sec, MeSec into H2Se.
DR   SABIO-RK; P35520; -.
DR   UniPathway; UPA00136; UER00201.
DR   ChiTaRS; CBS; human.
DR   EvolutionaryTrace; P35520; -.
DR   GeneWiki; Cystathionine_beta_synthase; -.
DR   PRO; PR:P35520; -.
DR   Proteomes; UP000005640; Chromosome 21.
DR   Bgee; ENSG00000160200; -.
DR   CleanEx; HS_CBS; -.
DR   ExpressionAtlas; P35520; baseline and differential.
DR   Genevisible; P35520; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0070025; F:carbon monoxide binding; IDA:BHF-UCL.
DR   GO; GO:0004122; F:cystathionine beta-synthase activity; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0020037; F:heme binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0072341; F:modified amino acid binding; IDA:UniProtKB.
DR   GO; GO:0070026; F:nitric oxide binding; IDA:BHF-UCL.
DR   GO; GO:0050421; F:nitrite reductase (NO-forming) activity; IDA:BHF-UCL.
DR   GO; GO:0019825; F:oxygen binding; IDA:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0030170; F:pyridoxal phosphate binding; IDA:UniProtKB.
DR   GO; GO:1904047; F:S-adenosyl-L-methionine binding; IDA:BHF-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0019344; P:cysteine biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0006535; P:cysteine biosynthetic process from serine; IEA:InterPro.
DR   GO; GO:0019343; P:cysteine biosynthetic process via cystathionine; IEA:InterPro.
DR   GO; GO:0042262; P:DNA protection; IMP:BHF-UCL.
DR   GO; GO:0043418; P:homocysteine catabolic process; IDA:UniProtKB.
DR   GO; GO:0050667; P:homocysteine metabolic process; IDA:UniProtKB.
DR   GO; GO:0070814; P:hydrogen sulfide biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0019448; P:L-cysteine catabolic process; IDA:UniProtKB.
DR   GO; GO:0006565; P:L-serine catabolic process; IDA:UniProtKB.
DR   GO; GO:0006563; P:L-serine metabolic process; IDA:UniProtKB.
DR   GO; GO:0019346; P:transsulfuration; TAS:Reactome.
DR   InterPro; IPR000644; CBS_dom.
DR   InterPro; IPR005857; Cysta_beta_synth.
DR   InterPro; IPR001216; P-phosphate_BS.
DR   InterPro; IPR001926; TrpB-like_PLP-dep.
DR   Pfam; PF00571; CBS; 1.
DR   Pfam; PF00291; PALP; 1.
DR   SMART; SM00116; CBS; 1.
DR   SUPFAM; SSF53686; SSF53686; 1.
DR   TIGRFAMs; TIGR01137; cysta_beta; 1.
DR   PROSITE; PS51371; CBS; 1.
DR   PROSITE; PS00901; CYS_SYNTHASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Allosteric enzyme; Alternative splicing;
KW   Amino-acid biosynthesis; CBS domain; Complete proteome;
KW   Cysteine biosynthesis; Cytoplasm; Disease mutation; Heme; Iron;
KW   Isopeptide bond; Lyase; Metal-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Pyridoxal phosphate; Reference proteome;
KW   Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:P32232}.
FT   CHAIN         2    551       Cystathionine beta-synthase.
FT                                /FTId=PRO_0000167133.
FT   DOMAIN      418    476       CBS. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00703}.
FT   REGION      256    260       Pyridoxal phosphate binding.
FT                                {ECO:0000269|PubMed:11483494,
FT                                ECO:0000269|PubMed:12173932}.
FT   METAL        52     52       Iron (heme axial ligand).
FT                                {ECO:0000269|PubMed:11483494,
FT                                ECO:0000269|PubMed:12173932}.
FT   METAL        65     65       Iron (heme axial ligand).
FT                                {ECO:0000269|PubMed:11483494,
FT                                ECO:0000269|PubMed:12173932}.
FT   BINDING     149    149       Pyridoxal phosphate.
FT                                {ECO:0000269|PubMed:11483494,
FT                                ECO:0000269|PubMed:12173932}.
FT   BINDING     349    349       Pyridoxal phosphate.
FT                                {ECO:0000269|PubMed:11483494,
FT                                ECO:0000269|PubMed:12173932}.
FT   MOD_RES      27     27       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES     119    119       N6-(pyridoxal phosphate)lysine.
FT                                {ECO:0000269|PubMed:11483494,
FT                                ECO:0000269|PubMed:12173932}.
FT   MOD_RES     199    199       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   CROSSLNK    211    211       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000269|PubMed:17087506}.
FT   VAR_SEQ     518    518       Y -> SQDQAWAGVVGGPAD (in isoform 2).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_001217.
FT   VARIANT      18     18       R -> C (functional polymorphism;
FT                                associated with 1/3 to 2/3 the enzyme
FT                                activity of the wild-type;
FT                                dbSNP:rs201827340).
FT                                {ECO:0000269|PubMed:16205833}.
FT                                /FTId=VAR_046921.
FT   VARIANT      49     49       P -> L (in CBSD; decreased expression; no
FT                                effect on cystathionine beta-synthase
FT                                activity; increased homotetramer
FT                                formation; dbSNP:rs148865119).
FT                                {ECO:0000269|PubMed:12124992,
FT                                ECO:0000269|PubMed:20506325,
FT                                ECO:0000269|PubMed:23974653}.
FT                                /FTId=VAR_008049.
FT   VARIANT      58     58       R -> W (in CBSD; linked with V-114; 18%
FT                                of activity; dbSNP:rs555959266).
FT                                {ECO:0000269|PubMed:10408774}.
FT                                /FTId=VAR_008050.
FT   VARIANT      65     65       H -> R (in CBSD; decreased cystathionine
FT                                beta-synthase activity; inhibited by
FT                                AdoMet and AdoHcy; decreased homotetramer
FT                                formation). {ECO:0000269|PubMed:11359213,
FT                                ECO:0000269|PubMed:20506325}.
FT                                /FTId=VAR_021790.
FT   VARIANT      69     69       A -> P (in dbSNP:rs17849313).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_046922.
FT   VARIANT      78     78       P -> R (in CBSD; severe form; linked with
FT                                Q-102; decreased cystathionine beta-
FT                                synthase activity; decreased homotetramer
FT                                formation; dbSNP:rs786204608).
FT                                {ECO:0000269|PubMed:20506325,
FT                                ECO:0000269|PubMed:7981678}.
FT                                /FTId=VAR_002171.
FT   VARIANT      85     85       G -> R (in CBSD; loss of cystathionine
FT                                beta-synthase activity;
FT                                dbSNP:rs863223435).
FT                                {ECO:0000269|PubMed:12007221,
FT                                ECO:0000269|PubMed:23981774}.
FT                                /FTId=VAR_008051.
FT   VARIANT      87     87       T -> N (in CBSD; decreased cystathionine
FT                                beta-synthase activity; increased
FT                                aggregation).
FT                                {ECO:0000269|PubMed:23981774}.
FT                                /FTId=VAR_074590.
FT   VARIANT      88     88       P -> S (in CBSD).
FT                                {ECO:0000269|PubMed:7762555}.
FT                                /FTId=VAR_002172.
FT   VARIANT     101    101       L -> P (in CBSD; common mutation in Irish
FT                                population; loss of activity;
FT                                dbSNP:rs786204757).
FT                                {ECO:0000269|PubMed:12124992,
FT                                ECO:0000269|PubMed:14635102,
FT                                ECO:0000269|PubMed:9889017}.
FT                                /FTId=VAR_021791.
FT   VARIANT     102    102       K -> N (in CBSD; decreased cystathionine
FT                                beta-synthase activity; decreased
FT                                homotetramer formation;
FT                                dbSNP:rs786204609).
FT                                {ECO:0000269|PubMed:20506325,
FT                                ECO:0000269|PubMed:7981678}.
FT                                /FTId=VAR_002173.
FT   VARIANT     102    102       K -> Q (in CBSD; severe form; linked with
FT                                R-78; dbSNP:rs34040148).
FT                                {ECO:0000269|PubMed:11013450}.
FT                                /FTId=VAR_008052.
FT   VARIANT     109    109       C -> R (in CBSD; loss of activity;
FT                                dbSNP:rs778220779).
FT                                {ECO:0000269|PubMed:12124992}.
FT                                /FTId=VAR_021792.
FT   VARIANT     114    114       A -> V (in CBSD; mild form; when linked
FT                                with W-58 severe form; decreased
FT                                cystathionine beta-synthase activity;
FT                                decreases homotetramer formation by
FT                                promoting formation of larger aggregates;
FT                                dbSNP:rs121964964).
FT                                {ECO:0000269|PubMed:11359213,
FT                                ECO:0000269|PubMed:20506325,
FT                                ECO:0000269|PubMed:8353501}.
FT                                /FTId=VAR_002174.
FT   VARIANT     116    116       G -> R (in CBSD; dbSNP:rs760214620).
FT                                {ECO:0000269|PubMed:8803779}.
FT                                /FTId=VAR_008053.
FT   VARIANT     121    121       R -> C (in CBSD; dbSNP:rs775992753).
FT                                /FTId=VAR_008054.
FT   VARIANT     121    121       R -> H (in CBSD; dbSNP:rs770095972).
FT                                /FTId=VAR_008055.
FT   VARIANT     121    121       R -> L (in CBSD; mild form;
FT                                dbSNP:rs770095972).
FT                                /FTId=VAR_008056.
FT   VARIANT     125    125       R -> P (in CBSD).
FT                                {ECO:0000269|PubMed:11553052}.
FT                                /FTId=VAR_046923.
FT   VARIANT     125    125       R -> Q (in CBSD; severe form; when linked
FT                                with D-131 moderate form; loss of
FT                                cystathionine beta-synthase activity;
FT                                decreased homotetramer formation;
FT                                dbSNP:rs781444670).
FT                                {ECO:0000269|PubMed:12124992,
FT                                ECO:0000269|PubMed:20506325,
FT                                ECO:0000269|PubMed:7762555,
FT                                ECO:0000269|PubMed:7849717}.
FT                                /FTId=VAR_002175.
FT   VARIANT     125    125       R -> W (in CBSD; exhibits an activity
FT                                lower than 4% of the wild-type enzyme;
FT                                absent capacity to form multimeric
FT                                quaternary structure).
FT                                {ECO:0000269|PubMed:12815602,
FT                                ECO:0000269|PubMed:16429402}.
FT                                /FTId=VAR_008057.
FT   VARIANT     126    126       M -> V (in CBSD; loss of activity).
FT                                {ECO:0000269|PubMed:10408774}.
FT                                /FTId=VAR_008058.
FT   VARIANT     128    128       E -> D (in CBSD).
FT                                /FTId=VAR_008059.
FT   VARIANT     131    131       E -> D (in CBSD; linked with Q-125; loss
FT                                of activity).
FT                                {ECO:0000269|PubMed:7849717}.
FT                                /FTId=VAR_002176.
FT   VARIANT     139    139       G -> R (in CBSD; mild form;
FT                                dbSNP:rs121964965).
FT                                {ECO:0000269|PubMed:7611293}.
FT                                /FTId=VAR_008060.
FT   VARIANT     143    143       I -> M (in CBSD; 4% of activity; stable).
FT                                {ECO:0000269|PubMed:15146473}.
FT                                /FTId=VAR_021793.
FT   VARIANT     144    144       E -> K (in CBSD; loss of cystathionine
FT                                beta-synthase activity; impaired
FT                                stimulation by AdoMet and AdoHcy;
FT                                decreased homotetramer formation;
FT                                dbSNP:rs121964966).
FT                                {ECO:0000269|PubMed:10215408,
FT                                ECO:0000269|PubMed:11359213,
FT                                ECO:0000269|PubMed:12124992,
FT                                ECO:0000269|PubMed:20506325,
FT                                ECO:0000269|PubMed:7611293,
FT                                ECO:0000269|PubMed:9156316}.
FT                                /FTId=VAR_002177.
FT   VARIANT     145    145       P -> L (in CBSD; dbSNP:rs121964963).
FT                                {ECO:0000269|PubMed:8353501}.
FT                                /FTId=VAR_002178.
FT   VARIANT     148    148       G -> R (in CBSD; loss of cystathionine
FT                                beta-synthase activity; impaired
FT                                stimulation by AdoMet and AdoHcy; loss of
FT                                homotetramer formation;
FT                                dbSNP:rs755952006).
FT                                {ECO:0000269|PubMed:15146473,
FT                                ECO:0000269|PubMed:16429402,
FT                                ECO:0000269|PubMed:20506325}.
FT                                /FTId=VAR_008061.
FT   VARIANT     151    159       Missing (in CBSD).
FT                                /FTId=VAR_008063.
FT   VARIANT     151    151       G -> R (in CBSD; dbSNP:rs373782713).
FT                                /FTId=VAR_008062.
FT   VARIANT     152    152       I -> M (in CBSD; severe form).
FT                                /FTId=VAR_008064.
FT   VARIANT     154    154       L -> Q (in CBSD; protein expression is
FT                                comparable to wild-type; significant
FT                                decrease of enzyme activity).
FT                                {ECO:0000269|PubMed:16205833}.
FT                                /FTId=VAR_046924.
FT   VARIANT     155    155       A -> T (in CBSD; complete loss of
FT                                activity; severely affects homotetramer
FT                                formation by promoting formation of
FT                                larger aggregates).
FT                                {ECO:0000269|PubMed:11359213}.
FT                                /FTId=VAR_008065.
FT   VARIANT     155    155       A -> V (in CBSD; protein expression is
FT                                comparable to wild-type; significant
FT                                decrease of enzyme activity).
FT                                {ECO:0000269|PubMed:16205833}.
FT                                /FTId=VAR_046925.
FT   VARIANT     165    165       C -> Y (in CBSD; severe form; protein
FT                                expression is comparable to wild-type;
FT                                loss of cystathionine beta-synthase
FT                                activity; no effect on homotetramer
FT                                formation). {ECO:0000269|PubMed:10215408,
FT                                ECO:0000269|PubMed:11359213,
FT                                ECO:0000269|PubMed:12124992,
FT                                ECO:0000269|PubMed:20506325,
FT                                ECO:0000269|PubMed:7635485}.
FT                                /FTId=VAR_002179.
FT   VARIANT     168    168       V -> A (in CBSD).
FT                                {ECO:0000269|PubMed:15993874}.
FT                                /FTId=VAR_046926.
FT   VARIANT     168    168       V -> M (in CBSD; dbSNP:rs121964970).
FT                                {ECO:0000269|PubMed:8528202}.
FT                                /FTId=VAR_002180.
FT   VARIANT     173    173       M -> V (in CBSD; presents 40% of the
FT                                wild-type activity; highly reduced
FT                                capacity to form multimeric quaternary
FT                                structure).
FT                                {ECO:0000269|PubMed:16429402}.
FT                                /FTId=VAR_046927.
FT   VARIANT     173    173       Missing (in CBSD; loss of activity).
FT                                {ECO:0000269|PubMed:21520339}.
FT                                /FTId=VAR_066098.
FT   VARIANT     176    176       E -> K (in CBSD; severe form; loss of
FT                                cystathionine beta-synthase activity;
FT                                inhibited by AdoMet; severely decreases
FT                                homotetramer formation by promoting
FT                                formation of larger aggregates).
FT                                {ECO:0000269|PubMed:11359213,
FT                                ECO:0000269|PubMed:20506325,
FT                                ECO:0000269|PubMed:9266356}.
FT                                /FTId=VAR_008066.
FT   VARIANT     180    180       V -> A (in CBSD; decreased cystathionine
FT                                beta-synthase activity; decreases
FT                                homotetramer formation).
FT                                {ECO:0000269|PubMed:20506325}.
FT                                /FTId=VAR_008067.
FT   VARIANT     191    191       T -> M (in CBSD; moderate and severe
FT                                forms; loss of cystathionine beta-
FT                                synthase activity; absent capacity to
FT                                form multimeric quaternary structure;
FT                                dbSNP:rs121964973).
FT                                {ECO:0000269|PubMed:12815602,
FT                                ECO:0000269|PubMed:15993874,
FT                                ECO:0000269|PubMed:16429402,
FT                                ECO:0000269|PubMed:20506325}.
FT                                /FTId=VAR_008068.
FT   VARIANT     198    198       D -> V (in CBSD).
FT                                /FTId=VAR_008069.
FT   VARIANT     200    200       P -> L (in CBSD; dbSNP:rs758712880).
FT                                {ECO:0000269|PubMed:21520339}.
FT                                /FTId=VAR_066099.
FT   VARIANT     224    224       R -> H (in CBSD; dbSNP:rs761647392).
FT                                {ECO:0000269|PubMed:8528202}.
FT                                /FTId=VAR_002181.
FT   VARIANT     226    226       A -> T (in CBSD; presents 20% of the
FT                                wild-type activity; dramatically reduced
FT                                capacity to form multimeric quaternary
FT                                structure). {ECO:0000269|PubMed:14635102,
FT                                ECO:0000269|PubMed:16429402}.
FT                                /FTId=VAR_008070.
FT   VARIANT     228    228       N -> K (in CBSD; loss of cystathionine
FT                                beta-synthase activity; decreased
FT                                homotetramer formation).
FT                                {ECO:0000269|PubMed:12124992,
FT                                ECO:0000269|PubMed:15146473,
FT                                ECO:0000269|PubMed:20506325,
FT                                ECO:0000269|PubMed:9889017}.
FT                                /FTId=VAR_021794.
FT   VARIANT     228    228       N -> S (in CBSD; has significantly
FT                                decreased levels of enzyme activity).
FT                                {ECO:0000269|PubMed:14635102}.
FT                                /FTId=VAR_046928.
FT   VARIANT     231    231       A -> P (in CBSD; has significantly
FT                                decreased levels of enzyme activity).
FT                                {ECO:0000269|PubMed:14635102}.
FT                                /FTId=VAR_046929.
FT   VARIANT     234    234       D -> N (in CBSD; decreased cystathionine
FT                                beta-synthase activity; changed
FT                                localization; decreased interaction with
FT                                pyridoxal 5'-phosphate; no effect on
FT                                homotetramer formation;
FT                                dbSNP:rs773734233).
FT                                {ECO:0000269|PubMed:23981774}.
FT                                /FTId=VAR_008071.
FT   VARIANT     234    234       Missing (in CBSD; protein expression is
FT                                comparable to wild-type; significant
FT                                decrease of enzyme activity).
FT                                {ECO:0000269|PubMed:16205833}.
FT                                /FTId=VAR_046930.
FT   VARIANT     239    239       E -> K (in CBSD).
FT                                /FTId=VAR_002182.
FT   VARIANT     247    256       Missing (in CBSD).
FT                                {ECO:0000269|PubMed:15365998}.
FT                                /FTId=VAR_046931.
FT   VARIANT     257    257       T -> M (in CBSD; moderate to severe form;
FT                                protein expression is comparable to wild-
FT                                type; significant decrease of enzyme
FT                                activity; dbSNP:rs758236584).
FT                                {ECO:0000269|PubMed:16205833,
FT                                ECO:0000269|PubMed:7762555}.
FT                                /FTId=VAR_002183.
FT   VARIANT     262    262       T -> M (in CBSD; moderate form;
FT                                dbSNP:rs149119723).
FT                                {ECO:0000269|PubMed:9361025,
FT                                ECO:0000269|PubMed:9889017}.
FT                                /FTId=VAR_008072.
FT   VARIANT     262    262       T -> R (in CBSD; severe form; loss of
FT                                cystathionine beta-synthase activity;
FT                                loss of homotetramer formation).
FT                                {ECO:0000269|PubMed:11013450,
FT                                ECO:0000269|PubMed:20506325}.
FT                                /FTId=VAR_021795.
FT   VARIANT     266    266       R -> G (in CBSD).
FT                                /FTId=VAR_008073.
FT   VARIANT     266    266       R -> K (in CBSD; mild form; decreased
FT                                cystathionine beta-synthase activity;
FT                                decreased homotetramer formation; no
FT                                effect on heme-binding; decreased
FT                                stability; dbSNP:rs28934275).
FT                                {ECO:0000269|PubMed:20506325,
FT                                ECO:0000269|PubMed:22738154,
FT                                ECO:0000269|PubMed:9361025}.
FT                                /FTId=VAR_008074.
FT   VARIANT     269    269       Missing (in CBSD; loss of expression).
FT                                {ECO:0000269|PubMed:23974653}.
FT                                /FTId=VAR_074591.
FT   VARIANT     270    270       Missing (in CBSD).
FT                                /FTId=VAR_008075.
FT   VARIANT     275    275       C -> Y (in CBSD; severe form; exhibits an
FT                                activity lower than 4% of the wild-type
FT                                enzyme; absent capacity to form
FT                                multimeric quaternary structure).
FT                                {ECO:0000269|PubMed:12815602,
FT                                ECO:0000269|PubMed:16429402}.
FT                                /FTId=VAR_021796.
FT   VARIANT     278    278       I -> S (in CBSD; loss of activity).
FT                                {ECO:0000269|PubMed:21520339}.
FT                                /FTId=VAR_066100.
FT   VARIANT     278    278       I -> T (in CBSD; mild to severe form;
FT                                common mutation; decreased expression;
FT                                loss of cystathionine beta-synthase
FT                                activity; impaired stimulation by AdoMet
FT                                and AdoHcy; severely affects homotetramer
FT                                formation by promoting formation of
FT                                larger aggregates; dbSNP:rs5742905).
FT                                {ECO:0000269|PubMed:11013450,
FT                                ECO:0000269|PubMed:11359213,
FT                                ECO:0000269|PubMed:12007221,
FT                                ECO:0000269|PubMed:12124992,
FT                                ECO:0000269|PubMed:1301198,
FT                                ECO:0000269|PubMed:14635102,
FT                                ECO:0000269|PubMed:15146473,
FT                                ECO:0000269|PubMed:15993874,
FT                                ECO:0000269|PubMed:20506325,
FT                                ECO:0000269|PubMed:21240075,
FT                                ECO:0000269|PubMed:23974653,
FT                                ECO:0000269|PubMed:7506602,
FT                                ECO:0000269|PubMed:7611293,
FT                                ECO:0000269|PubMed:8528202,
FT                                ECO:0000269|PubMed:8803779,
FT                                ECO:0000269|PubMed:9156316,
FT                                ECO:0000269|PubMed:9266356,
FT                                ECO:0000269|PubMed:9361025,
FT                                ECO:0000269|PubMed:9889017}.
FT                                /FTId=VAR_002184.
FT   VARIANT     281    281       D -> N (in CBSD; loss of activity).
FT                                {ECO:0000269|PubMed:21520339}.
FT                                /FTId=VAR_066101.
FT   VARIANT     288    288       A -> P (in CBSD).
FT                                {ECO:0000269|PubMed:15365998}.
FT                                /FTId=VAR_046932.
FT   VARIANT     288    288       A -> T (in CBSD; protein expression is
FT                                comparable to wild-type; significant
FT                                decrease of enzyme activity;
FT                                dbSNP:rs141502207).
FT                                {ECO:0000269|PubMed:16205833}.
FT                                /FTId=VAR_046933.
FT   VARIANT     290    290       P -> L (in CBSD; dbSNP:rs760912339).
FT                                {ECO:0000269|PubMed:7564249,
FT                                ECO:0000269|PubMed:8803779}.
FT                                /FTId=VAR_002185.
FT   VARIANT     302    302       E -> K (in CBSD; no effect on
FT                                cystathionine beta-synthase activity;
FT                                inhibited by AdoHcy and impaired
FT                                activation by AdoMet; no effect on
FT                                homotetramer formation;
FT                                dbSNP:rs779270933).
FT                                {ECO:0000269|PubMed:10408774,
FT                                ECO:0000269|PubMed:12124992,
FT                                ECO:0000269|PubMed:20506325}.
FT                                /FTId=VAR_008076.
FT   VARIANT     305    305       G -> R (in CBSD; loss of cystathionine
FT                                beta-synthase activity; no effect on
FT                                homotetramer formation).
FT                                {ECO:0000269|PubMed:20506325}.
FT                                /FTId=VAR_008077.
FT   VARIANT     307    307       G -> S (in CBSD; moderate to severe form;
FT                                linked with D-534; common mutation; loss
FT                                of cystathionine beta-synthase activity;
FT                                impaired stimulation by AdoMet and
FT                                AdoHcy; no effect on homotetramer
FT                                formation; dbSNP:rs121964962).
FT                                {ECO:0000269|PubMed:12124992,
FT                                ECO:0000269|PubMed:14635102,
FT                                ECO:0000269|PubMed:20506325,
FT                                ECO:0000269|PubMed:7506602,
FT                                ECO:0000269|PubMed:8528202,
FT                                ECO:0000269|PubMed:9266356,
FT                                ECO:0000269|PubMed:9361025,
FT                                ECO:0000269|PubMed:9889017}.
FT                                /FTId=VAR_002186.
FT   VARIANT     320    320       V -> A (in CBSD; has 36% of wild-type
FT                                enzyme activity; dbSNP:rs781567152).
FT                                {ECO:0000269|PubMed:14635102,
FT                                ECO:0000269|PubMed:9361025}.
FT                                /FTId=VAR_008078.
FT   VARIANT     321    321       D -> V (in CBSD; loss of activity).
FT                                {ECO:0000269|PubMed:21520339}.
FT                                /FTId=VAR_066102.
FT   VARIANT     331    331       A -> E (in CBSD; dbSNP:rs777919630).
FT                                {ECO:0000269|PubMed:12124992,
FT                                ECO:0000269|PubMed:9156316}.
FT                                /FTId=VAR_008079.
FT   VARIANT     331    331       A -> V (in CBSD).
FT                                {ECO:0000269|PubMed:8528202}.
FT                                /FTId=VAR_002187.
FT   VARIANT     336    336       R -> C (in CBSD; protein expression is
FT                                comparable to wild-type; loss of
FT                                activity; absent capacity to form
FT                                multimeric quaternary structure;
FT                                dbSNP:rs398123151).
FT                                {ECO:0000269|PubMed:10408774,
FT                                ECO:0000269|PubMed:12124992,
FT                                ECO:0000269|PubMed:12815602,
FT                                ECO:0000269|PubMed:16205833,
FT                                ECO:0000269|PubMed:16429402,
FT                                ECO:0000269|PubMed:21240075}.
FT                                /FTId=VAR_002188.
FT   VARIANT     336    336       R -> H (in CBSD; mild form; no effect on
FT                                expression; exhibits an activity lower
FT                                than 4% of the wild-type enzyme; altered
FT                                stimulation by AdoMet; absent capacity to
FT                                form multimeric quaternary structure;
FT                                dbSNP:rs760417941).
FT                                {ECO:0000269|PubMed:16429402,
FT                                ECO:0000269|PubMed:23974653}.
FT                                /FTId=VAR_008080.
FT   VARIANT     338    338       L -> P (in CBSD; severe form; exhibits an
FT                                activity lower than 4% of the wild-type
FT                                enzyme; absent capacity to form
FT                                multimeric quaternary structure).
FT                                {ECO:0000269|PubMed:12815602,
FT                                ECO:0000269|PubMed:16429402}.
FT                                /FTId=VAR_021797.
FT   VARIANT     347    347       G -> S (in CBSD; protein expression is
FT                                comparable to wild-type; loss of
FT                                activity; dbSNP:rs771298943).
FT                                {ECO:0000269|PubMed:12124992,
FT                                ECO:0000269|PubMed:16205833}.
FT                                /FTId=VAR_021798.
FT   VARIANT     349    349       S -> N (in CBSD; severe form; exhibits an
FT                                activity lower than 4% of the wild-type
FT                                enzyme; absent capacity to form
FT                                multimeric quaternary structure).
FT                                {ECO:0000269|PubMed:12815602,
FT                                ECO:0000269|PubMed:16429402}.
FT                                /FTId=VAR_021799.
FT   VARIANT     352    352       S -> N (in CBSD).
FT                                /FTId=VAR_008081.
FT   VARIANT     353    353       T -> M (in CBSD; protein expression is
FT                                comparable to wild-type; significant
FT                                decrease of enzyme activity;
FT                                dbSNP:rs121964972).
FT                                {ECO:0000269|PubMed:12124992,
FT                                ECO:0000269|PubMed:14635102,
FT                                ECO:0000269|PubMed:16205833,
FT                                ECO:0000269|PubMed:9156316}.
FT                                /FTId=VAR_008082.
FT   VARIANT     354    354       V -> M (in CBSD; dbSNP:rs267606146).
FT                                /FTId=VAR_008083.
FT   VARIANT     355    355       A -> P (in CBSD).
FT                                {ECO:0000269|PubMed:9889017}.
FT                                /FTId=VAR_021800.
FT   VARIANT     361    361       A -> T (in CBSD; dbSNP:rs745764562).
FT                                {ECO:0000269|PubMed:11553052}.
FT                                /FTId=VAR_046934.
FT   VARIANT     369    369       R -> C (in CBSD; when linked with C-491
FT                                severe form; decreased cystathionine
FT                                beta-synthase activity; decreased
FT                                homotetramer formation;
FT                                dbSNP:rs117687681).
FT                                {ECO:0000269|PubMed:12124992,
FT                                ECO:0000269|PubMed:20506325,
FT                                ECO:0000269|PubMed:9361025}.
FT                                /FTId=VAR_008084.
FT   VARIANT     369    369       R -> H (in CBSD; dbSNP:rs11700812).
FT                                /FTId=VAR_002189.
FT   VARIANT     370    370       C -> Y (in CBSD; dbSNP:rs757920190).
FT                                {ECO:0000269|PubMed:10462600}.
FT                                /FTId=VAR_008085.
FT   VARIANT     371    371       V -> M (in CBSD; dbSNP:rs372010465).
FT                                {ECO:0000269|PubMed:12124992,
FT                                ECO:0000269|PubMed:7635485}.
FT                                /FTId=VAR_002190.
FT   VARIANT     376    376       D -> N (in CBSD; has significantly
FT                                decreased levels of enzyme activity).
FT                                {ECO:0000269|PubMed:14635102}.
FT                                /FTId=VAR_046935.
FT   VARIANT     379    379       R -> Q (in CBSD; exhibits an activity
FT                                lower than 4% of the wild-type enzyme;
FT                                absent capacity to form multimeric
FT                                quaternary structure; dbSNP:rs763036586).
FT                                {ECO:0000269|PubMed:12815602,
FT                                ECO:0000269|PubMed:16429402}.
FT                                /FTId=VAR_021801.
FT   VARIANT     379    379       R -> W (in CBSD; dbSNP:rs769080151).
FT                                {ECO:0000269|PubMed:15365998}.
FT                                /FTId=VAR_046936.
FT   VARIANT     384    384       K -> E (in CBSD; severe form;
FT                                dbSNP:rs121964967).
FT                                {ECO:0000269|PubMed:8990018}.
FT                                /FTId=VAR_002191.
FT   VARIANT     384    384       K -> N (in CBSD; moderate form).
FT                                /FTId=VAR_008086.
FT   VARIANT     391    391       M -> I (in CBSD).
FT                                /FTId=VAR_008087.
FT   VARIANT     422    422       P -> L (in CBSD; changed cystathionine
FT                                beta-synthase activity; impaired
FT                                stimulation by AdoMet; does not affect
FT                                homotetramer formation;
FT                                dbSNP:rs28934892).
FT                                {ECO:0000269|PubMed:12007221,
FT                                ECO:0000269|PubMed:20506325}.
FT                                /FTId=VAR_021802.
FT   VARIANT     427    427       P -> L (in CBSD; no effect on
FT                                cystathionine beta-synthase activity;
FT                                altered stimulation by AdoMet;
FT                                dbSNP:rs863223434).
FT                                {ECO:0000269|PubMed:23974653,
FT                                ECO:0000269|PubMed:25044645}.
FT                                /FTId=VAR_074592.
FT   VARIANT     434    434       T -> N (in CBSD).
FT                                /FTId=VAR_008088.
FT   VARIANT     435    435       I -> T (in CBSD; no effect on
FT                                cystathionine beta-synthase activity;
FT                                impaired stimulation by AdoMet and
FT                                AdoHcy; does not affect homotetramer
FT                                formation). {ECO:0000269|PubMed:12007221,
FT                                ECO:0000269|PubMed:20506325}.
FT                                /FTId=VAR_008089.
FT   VARIANT     439    439       R -> Q (in CBSD; no effect on
FT                                cystathionine beta-synthase activity;
FT                                increased homotetramer formation;
FT                                dbSNP:rs756467921).
FT                                {ECO:0000269|PubMed:10462600,
FT                                ECO:0000269|PubMed:12124992,
FT                                ECO:0000269|PubMed:20506325,
FT                                ECO:0000269|PubMed:9156316}.
FT                                /FTId=VAR_008090.
FT   VARIANT     444    444       D -> N (in CBSD; decreased expression; no
FT                                effect on cystathionine beta-synthase
FT                                activity; altered stimulation by AdoMet;
FT                                increased homotetramer formation;
FT                                dbSNP:rs28934891).
FT                                {ECO:0000269|PubMed:12007221,
FT                                ECO:0000269|PubMed:20506325,
FT                                ECO:0000269|PubMed:23974653,
FT                                ECO:0000269|PubMed:25044645,
FT                                ECO:0000269|PubMed:8755636}.
FT                                /FTId=VAR_002192.
FT   VARIANT     446    446       A -> S (in CBSD).
FT                                {ECO:0000269|PubMed:21520339}.
FT                                /FTId=VAR_066103.
FT   VARIANT     449    449       V -> G (in CBSD; no effect on
FT                                cystathionine beta-synthase activity;
FT                                altered stimulation by AdoMet).
FT                                {ECO:0000269|PubMed:25044645}.
FT                                /FTId=VAR_074593.
FT   VARIANT     454    454       V -> E (in CBSD).
FT                                {ECO:0000269|PubMed:8528202}.
FT                                /FTId=VAR_002193.
FT   VARIANT     456    456       L -> P (in CBSD; severe; exhibits an
FT                                activity lower than 4% of the wild-type
FT                                enzyme; absent capacity to form
FT                                multimeric quaternary structure).
FT                                {ECO:0000269|PubMed:12815602,
FT                                ECO:0000269|PubMed:16429402}.
FT                                /FTId=VAR_021803.
FT   VARIANT     466    466       S -> L (in CBSD; increased cystathionine
FT                                beta-synthase activity; impaired
FT                                stimulation by AdoMet and AdoHcy;
FT                                decreased homotetramer formation;
FT                                dbSNP:rs121964971).
FT                                {ECO:0000269|PubMed:12007221,
FT                                ECO:0000269|PubMed:20506325}.
FT                                /FTId=VAR_008091.
FT   VARIANT     491    491       R -> C (in CBSD; linked with C-369).
FT                                /FTId=VAR_008092.
FT   VARIANT     500    500       S -> L (in CBSD; no effect on
FT                                cystathionine beta-synthase activity;
FT                                altered stimulation by AdoMet;
FT                                dbSNP:rs755106884).
FT                                {ECO:0000269|PubMed:23974653,
FT                                ECO:0000269|PubMed:25044645}.
FT                                /FTId=VAR_074594.
FT   VARIANT     526    526       Q -> K (in CBSD; has significantly
FT                                decreased levels of enzyme activity).
FT                                {ECO:0000269|PubMed:14635102}.
FT                                /FTId=VAR_046937.
FT   VARIANT     534    534       V -> D (in CBSD; linked with S-307).
FT                                /FTId=VAR_008093.
FT   VARIANT     539    539       L -> S (in CBSD; loss of cystathionine
FT                                beta-synthase activity; impaired
FT                                stimulation by AdoMet and AdoHcy; loss of
FT                                homotetramer formation;
FT                                dbSNP:rs121964968).
FT                                {ECO:0000269|PubMed:20506325,
FT                                ECO:0000269|PubMed:8990018}.
FT                                /FTId=VAR_002194.
FT   VARIANT     540    540       L -> Q (in CBSD; no effect on
FT                                cystathionine beta-synthase activity;
FT                                altered stimulation by AdoMet).
FT                                {ECO:0000269|PubMed:23974653,
FT                                ECO:0000269|PubMed:25044645}.
FT                                /FTId=VAR_074595.
FT   VARIANT     548    548       R -> Q (presents 60% of the wild-type
FT                                activity; highly reduced capacity to form
FT                                multimeric quaternary structure;
FT                                dbSNP:rs150828989).
FT                                {ECO:0000269|PubMed:16429402}.
FT                                /FTId=VAR_046938.
FT   MUTAGEN     272    272       C->A: Reduced heme content and
FT                                cystathionine beta-synthase activity.
FT                                {ECO:0000269|PubMed:12173932}.
FT   MUTAGEN     275    275       C->S: Reduced heme content and
FT                                cystathionine beta-synthase activity.
FT                                {ECO:0000269|PubMed:12173932}.
FT   CONFLICT     58     58       R -> P (in Ref. 4; CAA61252).
FT                                {ECO:0000305}.
FT   HELIX        60     62       {ECO:0000244|PDB:4COO}.
FT   STRAND       75     79       {ECO:0000244|PDB:4COO}.
FT   HELIX        80     82       {ECO:0000244|PDB:4COO}.
FT   STRAND       83     85       {ECO:0000244|PDB:4COO}.
FT   STRAND       89     91       {ECO:0000244|PDB:4COO}.
FT   HELIX        95     98       {ECO:0000244|PDB:4COO}.
FT   STRAND      103    109       {ECO:0000244|PDB:4COO}.
FT   HELIX       110    112       {ECO:0000244|PDB:4COO}.
FT   STRAND      113    117       {ECO:0000244|PDB:4L0D}.
FT   HELIX       119    132       {ECO:0000244|PDB:4COO}.
FT   STRAND      141    145       {ECO:0000244|PDB:4COO}.
FT   HELIX       149    161       {ECO:0000244|PDB:4COO}.
FT   STRAND      164    170       {ECO:0000244|PDB:4COO}.
FT   HELIX       175    183       {ECO:0000244|PDB:4COO}.
FT   STRAND      187    191       {ECO:0000244|PDB:4COO}.
FT   STRAND      197    199       {ECO:0000244|PDB:4L27}.
FT   HELIX       203    213       {ECO:0000244|PDB:4COO}.
FT   STRAND      217    219       {ECO:0000244|PDB:4L28}.
FT   TURN        222    224       {ECO:0000244|PDB:4COO}.
FT   HELIX       227    234       {ECO:0000244|PDB:4COO}.
FT   HELIX       236    243       {ECO:0000244|PDB:4COO}.
FT   TURN        244    246       {ECO:0000244|PDB:4COO}.
FT   STRAND      249    254       {ECO:0000244|PDB:4COO}.
FT   STRAND      256    258       {ECO:0000244|PDB:4COO}.
FT   HELIX       259    271       {ECO:0000244|PDB:4COO}.
FT   STRAND      272    274       {ECO:0000244|PDB:1M54}.
FT   STRAND      276    282       {ECO:0000244|PDB:4COO}.
FT   STRAND      288    290       {ECO:0000244|PDB:4COO}.
FT   HELIX       291    294       {ECO:0000244|PDB:4COO}.
FT   HELIX       317    319       {ECO:0000244|PDB:4COO}.
FT   STRAND      322    326       {ECO:0000244|PDB:4COO}.
FT   HELIX       328    342       {ECO:0000244|PDB:4COO}.
FT   HELIX       348    360       {ECO:0000244|PDB:4COO}.
FT   HELIX       361    363       {ECO:0000244|PDB:4COO}.
FT   STRAND      369    374       {ECO:0000244|PDB:4COO}.
FT   HELIX       378    381       {ECO:0000244|PDB:4COO}.
FT   TURN        382    386       {ECO:0000244|PDB:4COO}.
FT   HELIX       388    393       {ECO:0000244|PDB:4COO}.
FT   HELIX       399    404       {ECO:0000244|PDB:4COO}.
FT   TURN        408    411       {ECO:0000244|PDB:4UUU}.
FT   HELIX       414    417       {ECO:0000244|PDB:4UUU}.
FT   HELIX       431    441       {ECO:0000244|PDB:4UUU}.
FT   STRAND      444    449       {ECO:0000244|PDB:4UUU}.
FT   STRAND      455    460       {ECO:0000244|PDB:4UUU}.
FT   HELIX       461    469       {ECO:0000244|PDB:4UUU}.
FT   HELIX       479    482       {ECO:0000244|PDB:4UUU}.
FT   STRAND      489    491       {ECO:0000244|PDB:4UUU}.
FT   HELIX       496    505       {ECO:0000244|PDB:4UUU}.
FT   STRAND      509    515       {ECO:0000244|PDB:4UUU}.
FT   STRAND      526    534       {ECO:0000244|PDB:4UUU}.
FT   HELIX       536    544       {ECO:0000244|PDB:4UUU}.
SQ   SEQUENCE   551 AA;  60587 MW;  F89E69C67BDE6701 CRC64;
     MPSETPQAEV GPTGCPHRSG PHSAKGSLEK GSPEDKEAKE PLWIRPDAPS RCTWQLGRPA
     SESPHHHTAP AKSPKILPDI LKKIGDTPMV RINKIGKKFG LKCELLAKCE FFNAGGSVKD
     RISLRMIEDA ERDGTLKPGD TIIEPTSGNT GIGLALAAAV RGYRCIIVMP EKMSSEKVDV
     LRALGAEIVR TPTNARFDSP ESHVGVAWRL KNEIPNSHIL DQYRNASNPL AHYDTTADEI
     LQQCDGKLDM LVASVGTGGT ITGIARKLKE KCPGCRIIGV DPEGSILAEP EELNQTEQTT
     YEVEGIGYDF IPTVLDRTVV DKWFKSNDEE AFTFARMLIA QEGLLCGGSA GSTVAVAVKA
     AQELQEGQRC VVILPDSVRN YMTKFLSDRW MLQKGFLKEE DLTEKKPWWW HLRVQELGLS
     APLTVLPTIT CGHTIEILRE KGFDQAPVVD EAGVILGMVT LGNMLSSLLA GKVQPSDQVG
     KVIYKQFKQI RLTDTLGRLS HILEMDHFAL VVHEQIQYHS TGKSSQRQMV FGVVTAIDLL
     NFVAAQERDQ K
//
